7 completed, 3 terminated, 3 unknown, 2 withdrawn. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 7, Terminated 3, Unknown 3, Withdrawn 2, Enrolling by invitation 1 |
Follow Ceftaroline: new trials by email Literature Review of Ceftaroline trials Research Report on Ceftaroline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia | Phase 4 | Enrolling by invitation | West Virginia University | 300 | 2025-09-15 | 2026-09-17 |
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis | Phase 4 | Terminated | West Virginia University | 5 | 2022-03-16 | 2026-05-05 |
| Antibiotic Prophylaxis in Open Fractures Ceftaroline - Open Fractures | Phase 4 | Unknown | Olayemi Osiyemi MD | 50 | 2016-12-01 | 2016-10-28 |
| IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB Daptomycin, Vancomycin, Ceftaroline - Bacteremia | Phase 4 | Completed | Sharp HealthCare | 40 | 2015-11-01 | 2018-02-01 |
| The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection Ceftaroline, Cefazolin / Vancomycin - Surgical Site Infection | Phase 4 | Unknown | University of Cincinnati | 500 | 2015-01-01 | 2015-12-02 |
| Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy Ceftaroline in CRRT, Ceftaroline in IRRT - Infection During Renal Replacement Therapy | Phase 4 | Unknown | Medical University of Vienna | 25 | 2013-12-01 | 2022-04-14 |
| Ceftaroline in the Treatment of Bone and Joint Infections Ceftaroline - Osteomyelitis, Joint Infections | Phase 4 | Withdrawn | Orlando Health, Inc. | 2013-04-01 | 2014-08-07 | |
| Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia Ceftaroline fosamil - Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia | Phase 4 | Completed | Forest Laboratories | 56 | 2013-01-01 | 2014-07-31 |
| Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia Ceftaroline fosamil - Community-Acquired Bacterial Pneumonia (CABP) | Phase 4 | Withdrawn | Forest Laboratories | 2012-11-01 | 2013-02-11 | |
| Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus Ceftaroline fosamil, Ceftriaxone plus vancomycin - Infections | Phase 4 | Completed | Forest Laboratories | 49 | 2012-10-01 | 2016-02-01 |
| Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP) Ceftaroline fosamil, IV Ceftriaxone and Vancomycin - Infections, Pneumonia | Phase 4 | Completed | Forest Laboratories | 40 | 2012-10-01 | 2015-11-02 |
| Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia Ceftaroline, Levofloxacin - Pneumonia, Bacterial, Community-acquired | Phase 4 | Completed | Gary E. Stein, Pharm.D. | 12 | 2012-02-01 | 2016-04-12 |
| Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA Ceftaroline, Vancomycin - Skin Diseases, Infectious, Staphylococcal Skin Infections | Phase 4 | Completed | Wayne State University | 174 | 2012-02-01 | 2016-11-01 |
| Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Vancomycin, Ceftaroline, Daptomycin - Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis | Phase 4 | Terminated | Henry Ford Health System | 100 | 2011-10-01 | 2023-05-03 |
| Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital Ceftaroline fosamil - Infections | Phase 4 | Completed | Forest Laboratories | 53 | 2011-04-01 | 2014-05-14 |
Infections (5) · Bacteremia (3) · Pneumonia (3) · Endocarditis (2) · Osteomyelitis (2) · Arthritis, Infectious (1) · Community-Acquired Pneumonia (1) · Fractures, Open (1) · Pneumonia, Bacterial (1) · Skin Diseases, Infectious (1) · Soft Tissue Infections (1) · Staphylococcal Skin Infections (1) · Surgical Wound Infection (1)
Forest Laboratories (5) · West Virginia University (3) · Gary E. Stein, Pharm.D. (1) · Henry Ford Health System (1) · Medical University of Vienna (1) · Olayemi Osiyemi MD (1) · Orlando Health, Inc. (1) · Sharp HealthCare (1) · University of Cincinnati (1) · Wayne State University (1)
United States (14) · Georgia (2) · Ukraine (2) · Argentina (1) · Austria (1) · Hungary (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1)
Alan G Smulian, M.B.B.Ch. (1) · Arif R Sawari, MD, MSc, MBA (1) · Arif R. Sarwari, MD, MSc, MBA (1) · DeAnn Cary, PhD (1) · Gary E Stein, Pharm.D. (1) · Jose Vazquez, M.D. (1) · Joy J Juskowich, MD (1) · Joy J. Juskowich, MD (1) · Mark R. Wallace, MD (1) · Michael Rybak, PharmD, MPH (1) · Olayemi Osiyemi, MD (1) · Vinay Badhwar, MD (1)